PubMed日本語 - 人口に基づいた症例対照研究:プロトンポンプ抑制とビスホスホネートの使用による股関節部骨折のリスク。―QLifePro医療翻訳医療翻訳 QLifePro



A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.

Published date 2013 Jan 11

A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.


Published date



Joongyub Lee, KyungEun Youn, Nam-Kyong Choi, Jin-Ho Lee, DongYoon Kang, Hong-Ji Song, Byung-Joo Park


Clinical Epidemiology Division, Medical Research Collaborating Center, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea.


BACKGROUND: Studies on the risk of osteoporotic fractures related to the use of proton pump inhibitors (PPIs) have been inconsistent. One recent cohort study reported that there was an interaction between PPIs and bisphosphonates (BPs). Thus we performed a case-control study aimed at evaluating the risk of hip fractures related to PPIs and exploring the interaction between PPIs and BPs.


METHODS: A case-control study was performed using the Korean Health Insurance Review and Assessment Service database from 2005 January to 2006 June. The cases were all incident hip fractures identified from July 2005 to June 2006, and up to four controls were matched to each case by age, gender, and osteoporosis. Conditional logistic regression was used to calculate the adjusted odds ratio (aOR) and its 95 % confidence intervals.


RESULTS: A total of 24,710 cases were identified and 98,642 controls were matched to the cases. The aOR and its 95 % CI of hip fractures related to the use of PPIs was 1.34 (95 % CI 1.24-1.44). When the study participants were stratified according to BP use, the aOR was 1.30 (95 % CI 1.19-1.42) in BP non-users, which was significantly different from the 1.71 (95 % CI 1.31-2.23) of BP users. Only BP users showed a decreasing tendency toward fracture risk as exposure to PPI became less recent, and a trend of increasing risk with increasing cumulative doses.


CONCLUSIONS: Our results suggest that the mechanism for increased risk of hip fracture by PPIs may arise mainly from interaction of BP and PPIs.




aORとPPIの使用に関連した股関節部骨折のその95%CIは、1.34(95%CI 1.24-1.44)であった。
試験参加者が血圧使用によって層化されたとき、aORは血圧非使用者における1.30(95%CI 1.19-1.42)であった。
そして、それは血圧使用者の1.71人(95%CI 1.31-2.23)と有意に異なった。


460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳